Marta Massanella1, Thanyawee Puthanakit2,3, Louise Leyre1, Thidarat Jupimai2, Panadda Sawangsinth4, Mark de Souza4, Piyarat Suntarattiwong5, Pope Kosalarksa6, Thitiporn Borkird7, Suparat Kanjanavanit8, Kulkanya Chokephaibulkit9, Rawiwan Hansudewechakul10, Witaya Petdachai11, Julie L Mitchell12,13,14, Merlin L Robb12,13, Lydie Trautmann12,13,14, Jintanat Ananworanich5,12,13,15, Nicolas Chomont1. 1. Centre de Recherche du Centre hospitalier de l'Université de Montréal and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Canada. 2. Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 3. HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 4. SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 5. Queen Sirikit National Institute of Child Health, Bangkok, Thailand. 6. Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 7. Hat Yai Hospital, Songkla, Thailand. 8. Nakornping Hospital, Chiang Mai, Thailand. 9. Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 10. Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 11. Phrachomklao Hospital, Petchaburi, Thailand. 12. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA. 13. United States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. 14. Vaccine and Gene Therapy Institute, Oregon Health and Science University, Hillsboro, Oregon, USA. 15. Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA.
Abstract
BACKGROUND: Early antiretroviral therapy (ART) restricts the size of the human immunodeficiency virus (HIV) reservoir in infants. However, whether antiretroviral (ARV) prophylaxis given to exposed vertically infected children exerts similar effects remains unknown. METHODS: We measured total and integrated HIV DNA, as well as the frequency of CD4 T cells producing multiply spliced RNA (msRNA) after stimulation (inducible reservoir) in vertically infected Thai infants. Eighty-five infants were followed longitudinally for up to 3 years. We compared the size of the reservoir in children who received continuous ARV prophylaxis since birth vs those who never received or discontinued prophylaxis before initiating ART. We used samples from a cross-sectional cohort of 37 Thai children who had initiated ART within 6 months of life to validate our findings. RESULTS: Before ART, levels of HIV DNA and the frequencies of cells producing msRNA were significantly lower in infants who received continuous ARV prophylaxis since birth compared to those in whom ARV prophylaxis was discontinued or never initiated (P < .020 and P < .001, respectively). Upon ART initiation, total and integrated HIV DNA levels decayed significantly in both groups (P < .01 in all cases). Interestingly, the initial differences in the frequencies of infected cells persisted during 3 years on ART. The beneficial effect of prophylaxis on the size of the HIV reservoir was confirmed in the cross-sectional study. Importantly, no differences were observed between children who discontinued prophylactic ARVs before starting ART and those who delayed ART initiation without receiving prior prophylaxis. CONCLUSIONS: Neonatal ARV prophylaxis with direct transition to ART durably limits the size of the HIV reservoir.
BACKGROUND: Early antiretroviral therapy (ART) restricts the size of the human immunodeficiency virus (HIV) reservoir in infants. However, whether antiretroviral (ARV) prophylaxis given to exposed vertically infectedchildren exerts similar effects remains unknown. METHODS: We measured total and integrated HIV DNA, as well as the frequency of CD4 T cells producing multiply spliced RNA (msRNA) after stimulation (inducible reservoir) in vertically infected Thai infants. Eighty-five infants were followed longitudinally for up to 3 years. We compared the size of the reservoir in children who received continuous ARV prophylaxis since birth vs those who never received or discontinued prophylaxis before initiating ART. We used samples from a cross-sectional cohort of 37 Thai children who had initiated ART within 6 months of life to validate our findings. RESULTS: Before ART, levels of HIV DNA and the frequencies of cells producing msRNA were significantly lower in infants who received continuous ARV prophylaxis since birth compared to those in whom ARV prophylaxis was discontinued or never initiated (P < .020 and P < .001, respectively). Upon ART initiation, total and integrated HIV DNA levels decayed significantly in both groups (P < .01 in all cases). Interestingly, the initial differences in the frequencies of infected cells persisted during 3 years on ART. The beneficial effect of prophylaxis on the size of the HIV reservoir was confirmed in the cross-sectional study. Importantly, no differences were observed between children who discontinued prophylactic ARVs before starting ART and those who delayed ART initiation without receiving prior prophylaxis. CONCLUSIONS: Neonatal ARV prophylaxis with direct transition to ART durably limits the size of the HIV reservoir.
Authors: M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong Journal: Proc Natl Acad Sci U S A Date: 2003-04-08 Impact factor: 11.205
Authors: Gert U van Zyl; Margaret A Bedison; Anita Janse van Rensburg; Barbara Laughton; Mark F Cotton; John W Mellors Journal: J Infect Dis Date: 2014-12-23 Impact factor: 5.226
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Priyanka Uprety; Kunjal Patel; Brad Karalius; Carrie Ziemniak; Ya Hui Chen; Sean S Brummel; Suzanne Siminski; Russell B Van Dyke; George R Seage; Deborah Persaud Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079
Authors: Margaret McManus; Eric Mick; Richard Hudson; Lynne M Mofenson; John L Sullivan; Mohan Somasundaran; Katherine Luzuriaga Journal: PLoS One Date: 2016-04-22 Impact factor: 3.240
Authors: Helen Payne; Man K Chan; Sarah A Watters; Kennedy Otwombe; Nei-Yuan Hsiao; Abdel Babiker; Avy Violari; Mark F Cotton; Diana M Gibb; Nigel J Klein Journal: AIDS Res Ther Date: 2021-09-29 Impact factor: 2.250